MA51733A - Composition contraceptive présentant des effets cardiovasculaires réduits - Google Patents

Composition contraceptive présentant des effets cardiovasculaires réduits

Info

Publication number
MA51733A
MA51733A MA051733A MA51733A MA51733A MA 51733 A MA51733 A MA 51733A MA 051733 A MA051733 A MA 051733A MA 51733 A MA51733 A MA 51733A MA 51733 A MA51733 A MA 51733A
Authority
MA
Morocco
Prior art keywords
cardiovascular effects
contraceptive composition
reduced cardiovascular
reduced
contraceptive
Prior art date
Application number
MA051733A
Other languages
English (en)
Inventor
Maud Jost
Glwadys Rausin
Original Assignee
Estetra Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Estetra Sprl filed Critical Estetra Sprl
Publication of MA51733A publication Critical patent/MA51733A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
MA051733A 2018-02-07 2019-02-07 Composition contraceptive présentant des effets cardiovasculaires réduits MA51733A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18155571 2018-02-07
EP18160586 2018-03-07

Publications (1)

Publication Number Publication Date
MA51733A true MA51733A (fr) 2020-12-16

Family

ID=65278388

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051733A MA51733A (fr) 2018-02-07 2019-02-07 Composition contraceptive présentant des effets cardiovasculaires réduits

Country Status (20)

Country Link
EP (2) EP3749327A1 (fr)
JP (2) JP2021513507A (fr)
KR (1) KR102717921B1 (fr)
CN (2) CN115429806A (fr)
AU (1) AU2019219070B2 (fr)
CA (2) CA3089804A1 (fr)
CL (1) CL2020002017A1 (fr)
EC (1) ECSP20054822A (fr)
GE (2) GEAP202215414A (fr)
IL (1) IL276584B2 (fr)
JO (1) JOP20200169A1 (fr)
MA (1) MA51733A (fr)
NZ (1) NZ766027A (fr)
PH (1) PH12020500601A1 (fr)
PY (1) PY1908892A (fr)
SG (1) SG11202007163WA (fr)
TW (1) TWI845496B (fr)
UA (1) UA126746C2 (fr)
UY (1) UY38075A (fr)
WO (1) WO2019154899A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3701944B1 (fr) 2015-06-18 2021-12-08 Estetra SRL Unité posologique orodispersible contenant un composant d'estétrol
MA44206B1 (fr) 2015-06-18 2021-04-30 Estetra Sprl Comprimé orodispersible comprenant estetrol
CU24523B1 (es) 2015-06-18 2021-06-08 Estetra Sprl Unidad de dosificación orodispersable que contiene un componente estetrol
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
CA3178291A1 (fr) 2016-08-05 2018-04-12 Estetra Srl Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles
EP3781171B1 (fr) 2018-04-19 2022-02-09 Estetra SRL Composés et leurs utilisations pour soulager des symptômes associés à la ménopause
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
WO2022248733A1 (fr) 2021-05-28 2022-12-01 Neuralis Sa Utilisation d'estétrol dans le traitement de maladies infectieuses respiratoires

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
DK1390042T3 (da) * 2001-05-23 2008-03-31 Pantarhei Bioscience Bv System for administration af et lægemiddel omfattende tetrahydroxyleret östrogen til anvendelse i hormonal svangerskabsforebyggelse
EP1535618A1 (fr) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Préparation pharmaceutique pour le traitement hormonal continuel sur plus de 21-28 jours comprenant deux compositions d'estrogène et/ou de progestine
EP2432474A1 (fr) * 2009-05-22 2012-03-28 Bayer Pharma Aktiengesellschaft Médicament à administrer oralement, contenant au moins un strogène et/ou au moins un gestagène et au moins une souche bactérienne probiotique
WO2012055840A1 (fr) * 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition et préparation pour le traitement de la dysménorrhée et de la douleur menstruelle et utilisation d'un agent hormonal et d'un sel de zinc pour le traitement de troubles menstruels
DK3079671T3 (en) * 2013-12-12 2017-12-11 Donesta Bioscience B V Orally disintegrating solid dosage unit containing an estetrol component
CA3178291A1 (fr) * 2016-08-05 2018-04-12 Estetra Srl Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles
KR102780201B1 (ko) 2016-10-28 2025-03-12 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법

Also Published As

Publication number Publication date
KR102717921B1 (ko) 2024-10-16
IL276584A (en) 2020-09-30
PY1908892A (es) 2019-10-15
GEAP202215414A (en) 2022-04-25
AU2019219070B2 (en) 2024-12-19
IL276584B2 (en) 2024-10-01
CN111683664A (zh) 2020-09-18
CL2020002017A1 (es) 2020-12-04
WO2019154899A1 (fr) 2019-08-15
PH12020500601A1 (en) 2021-05-17
UY38075A (es) 2019-10-01
SG11202007163WA (en) 2020-08-28
JOP20200169A1 (ar) 2020-07-07
CA3178181A1 (fr) 2019-08-15
KR20200118464A (ko) 2020-10-15
JP2024009834A (ja) 2024-01-23
JP2021513507A (ja) 2021-05-27
JP7651645B2 (ja) 2025-03-26
NZ766027A (en) 2026-03-27
ECSP20054822A (es) 2020-12-31
EP4140489A1 (fr) 2023-03-01
IL276584B1 (en) 2024-06-01
CN115429806A (zh) 2022-12-06
EP3749327A1 (fr) 2020-12-16
UA126746C2 (uk) 2023-01-18
AU2019219070A1 (en) 2020-09-24
GEP20227407B (en) 2022-08-25
CA3089804A1 (fr) 2019-08-15
TWI845496B (zh) 2024-06-21
TW202011967A (zh) 2020-04-01

Similar Documents

Publication Publication Date Title
IL276584A (en) A contraceptive with a reduced cardiovascular effect
EP3722358A4 (fr) Composition
DK3697376T3 (da) Sammensætning
EP3478777A4 (fr) Composition formant un film diélecttrique
EP3853332C0 (fr) Composition
EP3981255A4 (fr) Composition nutritionnelle
EP3882323A4 (fr) Composition
IL262390A (en) Semaglutide in cardiovascular conditions
DK3840596T3 (da) Sammensætning
EP3636081A4 (fr) Composition alimentaire
ITUA20162751A1 (it) Composizione secca in polvere
EP3897866C0 (fr) Composition antimicrobienne
DK3459354T3 (da) Glyceridsammensætning
EP3675653C0 (fr) Composition antimycotoxine
DK3423082T5 (da) Liraglutid ved kardiovaskulære tilstande
EP3868869A4 (fr) Composition nutritionnelle
EP3900790A4 (fr) Composition
DK3623432T3 (da) Sammensætning
EP3846831C0 (fr) Compositions d'associations de probiotiques
EP3623430C0 (fr) Composition
PL3752598T3 (pl) Kompozycja allogeniczna
EP3782632A4 (fr) Composition anti-stress
EP3808785A4 (fr) Composition
DK3576546T3 (da) Probiotisk sammensætning
ES1209313Y (es) Composicion liofilizada